Recent Press Releases

Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman

Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman Bristol-Myers Squibb Media:Jennifer Fron Mauer, 609-252-6579 or...

Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIV

Eisai Launches New Savings Card to Increase Access and Affordability of BELVIQ® (lorcaserin HCl) CIV Card Enables Eligible Patients to Pay No More than $75 for their BELVIQ Prescription*...

Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results:

2014 Fourth-Quarter Sales of $18.3 Billion Decreased 0.6%; EPS was $0.89 2014 Full-Year Sales of $74.3 Billion Increased 4.2%; Full-Year EPS was $5.70 Excluding Special Items, 2014 Fourth-Quarter EPS...

European Label Update of Bayer's Xarelto(R) Now Including Guidance for Use in Patients with Atrial Fibrillation Undergoing Cardioversion

BERLIN, Jan. 20, 2015 /PRNewswire/ -- Bayer HealthCare today announced the inclusion of specific guidance for doctors treating patients with non-valvular atrial fibrillation (AF) undergoing...

Johnson & Johnson Announces Formation of Ebola Vaccine Development Consortia, Gains Funding from Innovative Medicines Initiative

Consortia funded through the IMI Ebola+ Programme Supported by the European Commission

NEW BRUNSWICK, N.J.,

Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion

SOURCE Depomed, Inc. Conference call today at 5:00 p.m. EST - Transformative acquisition enhances Depomed's position as a leading pain and neurology focused specialty pharmaceutical company -...

Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution

TITUSVILLE, N.J., Jan. 15, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (JPI) today announced it has entered into a definitive agreement with Depomed, Inc. to divest its U.S. license rights to...

European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C

In Phase 3 clinical trials, VIEKIRAX + EXVIERA cured 95-100 percent of genotype 1 chronic hepatitis C patients, with less than 2 percent of patients experiencing virologic failure[1],[2] -...

MICROVAX CANCER VACCINE FIRST IN HUMAN CLINICAL TRIAL IN SINGAPORE

Singapore, 12 August 2014 – MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine...

Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer

Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab

THOUSAND

Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion

Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for...

Vince & Associates Clinical Research Joins Cardiac Safety Research Consortium

Vince & Associates Clinical Research Joins Cardiac Safety Research Consortium

Vince & Associates Clinical Research

jcabana@vinceandassociates.com

Vince & Associates Clinical Research Joins Cardiac Safety Research Consortium

Overland Park, Kansas - Vince & Associates Clinical Research announced today its membership into the Cardiac Safety Research Consortium (CSRC). As a member of the CSRC, Vince & Associates...

Gilead Denied Patent for Hepatitis C drug sofosbuvir in India

The Indian Patent Controller today rejected one of Gilead's key patent applications which covered the drug sofosbuvir, used to treat hepatitis C (HCV). The oral drug, which first received regulatory...

Sanofi Enters Strategic Manufacturing Collaboration with Boehringer Ingelheim To Produce Biologics

Sanofi Enters Strategic Manufacturing Collaboration with Boehringer Ingelheim To Produce Biologics Paris, France - January 15, 2015 - Sanofi announced today it has entered into a strategic...

Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals

Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals Ingelheim, Germany - 15 January 2015 - Boehringer Ingelheim and Sanofi...

Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples

LA JOLLA, Calif., Jan. 14, 2015 /PRNewswire/ -- Human Longevity, Inc.